New molecular therapy targets in acute myeloid leukemia.
Despite improvements to acute myelogenous leukemia (AML) therapy during the last 25 years, the majority of patients still succumb to the disease. Thus, there remains an urgent need for further improvements in this field. The present chapter focuses on exciting areas of research in the field of AML therapy, including promising results with regards to recent improvements in our understanding of angiogenesis, tyrosine kinase signaling, farnesylation, cell cycling, modulation of gene expression, protein degradation, modulation of intracellular proteins, apoptosis, metabolism, and the possible retargeting of oncogenic proteins.
Krug
Utz
U
Medizinische Klinik A, Universitätsklinikum Münster, Germany.
Serve
Hubert
H
Müller-Tidow
Carsten
C
Mesters
Rolf M
RM
Steffen
Björn
B
Büchner
Thomas
T
Berdel
Wolfgang E
WE
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism*; D009857:Oncogenes / Q000187:drug effects; D011506:Proteins / Q000187:drug effects; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D011506:Proteins; D020794:Receptor Protein-Tyrosine Kinases